Copertina

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Pranab M. Barman
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
di: Sarah Flatley
Pubblicazione: (2026)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
di: Muhammad Ibrahim Khalil, et al.
Pubblicazione: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
di: Seren Gedallovich, et al.
Pubblicazione: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective
di: Yassine Kilani, et al.
Pubblicazione: (2024)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
di: Ze‐Hua Zhao, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
di: Ganesh Bhat, et al.
Pubblicazione: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
di: Amol N. Patil, et al.
Pubblicazione: (2026)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt
di: Michelle Spaan, et al.
Pubblicazione: (2025)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
di: Stefan Mauss
Pubblicazione: (2025)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
di: Hariti Saluja, et al.
Pubblicazione: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
di: Catherine Jia Lin Tian, et al.
Pubblicazione: (2024)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
di: Yu Jun Wong
Pubblicazione: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
di: Rónán O'Connor, et al.
Pubblicazione: (2026)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
di: Miriam T. Levy
Pubblicazione: (2026)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
di: Wei‐Fan Hsu, et al.
Pubblicazione: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
di: Thomas Hoang, et al.
Pubblicazione: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
di: Tanat Saeoui, et al.
Pubblicazione: (2025)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis
di: Maaz Arif, et al.
Pubblicazione: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
di: Marta Paula Pereira Coelho, et al.
Pubblicazione: (2024)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
di: Thanawin Pramotedham, et al.
Pubblicazione: (2026)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
di: Jian Wang, et al.
Pubblicazione: (2025)

Editorial: Hepatitis D Screening—DAS (Delta Virus Awareness and Screening) Approach in Primary Care
di: Noreen Singh, et al.
Pubblicazione: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
di: J. Ventre, et al.
Pubblicazione: (2025)

Editorial: Terlipressin Induced Bradycardia
di: Nancy Reau, et al.
Pubblicazione: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
di: YaoYao Dai, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
di: Shun‐Ichi Wakabayashi, et al.
Pubblicazione: (2026)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
di: Vincent Mallet, et al.
Pubblicazione: (2025)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
di: Shiva Poola, et al.
Pubblicazione: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)